D. E. Shaw & Co. Inc. Sells 554,092 Shares of The Beauty Health Company (NASDAQ:SKIN)

D. E. Shaw & Co. Inc. lessened its position in shares of The Beauty Health Company (NASDAQ:SKIN - Free Report) by 32.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,171,749 shares of the company's stock after selling 554,092 shares during the period. D. E. Shaw & Co. Inc. owned about 0.94% of Beauty Health worth $1,863,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the company. Bridgeway Capital Management LLC boosted its stake in shares of Beauty Health by 13.6% during the 4th quarter. Bridgeway Capital Management LLC now owns 1,211,600 shares of the company's stock worth $1,926,000 after buying an additional 145,000 shares during the last quarter. Renaissance Technologies LLC acquired a new position in shares of Beauty Health during the 4th quarter worth about $64,000. Mirabella Financial Services LLP acquired a new position in shares of Beauty Health during the 4th quarter worth about $14,292,000. SG Americas Securities LLC boosted its stake in shares of Beauty Health by 38.2% during the 4th quarter. SG Americas Securities LLC now owns 35,290 shares of the company's stock worth $56,000 after buying an additional 9,749 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its stake in shares of Beauty Health by 19.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 114,147 shares of the company's stock worth $182,000 after buying an additional 18,400 shares during the last quarter. Institutional investors own 93.26% of the company's stock.

Analyst Ratings Changes

Separately, Canaccord Genuity Group reduced their price objective on shares of Beauty Health from $1.50 to $1.25 and set a "hold" rating for the company in a research note on Monday, May 5th.

Beauty Health Trading Down 7.7%

Shares of NASDAQ:SKIN opened at $1.56 on Thursday. The Beauty Health Company has a 52-week low of $0.78 and a 52-week high of $2.76. The company has a market capitalization of $195.38 million, a P/E ratio of -3.71 and a beta of 0.88. The company has a 50-day simple moving average of $1.23 and a 200 day simple moving average of $1.45. The company has a debt-to-equity ratio of 9.23, a quick ratio of 5.57 and a current ratio of 6.56.

Beauty Health (NASDAQ:SKIN - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.05. Beauty Health had a negative net margin of 8.11% and a negative return on equity of 44.83%. The business had revenue of $69.60 million during the quarter, compared to the consensus estimate of $63.88 million. Sell-side analysts forecast that The Beauty Health Company will post -0.25 earnings per share for the current year.

Beauty Health Company Profile

The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.